Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Enveric Biosciences Inc
(NQ:
ENVB
)
0.3311
-0.0022 (-0.66%)
Streaming Delayed Price
Updated: 11:26 AM EST, Nov 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Enveric Biosciences Inc
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Enveric Biosciences Advances Non-Hallucinogenic DMT Analog Drug With Promising Preclinical Results
Today 9:00 EST
Via
Benzinga
Enveric Biosciences Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability, Demonstrate Brain Penetration, and Show No Evidence of Hallucination-like Behavior
Today 9:00 EST
From
Enveric Biosciences, Inc.
Via
Business Wire
Why Symbotic Shares Are Trading Higher By Over 28%; Here Are 20 Stocks Moving Premarket
November 19, 2024
Via
Benzinga
Enveric Biosciences Trims Losses, Eyes Key Drug Approval For Difficult-To-Treat Mental Health Disorders
November 18, 2024
Via
Benzinga
Why Is Enveric Biosciences (ENVB) Stock Up 18% Today?
July 30, 2024
Enveric Biosciences stock is up on Tuesday with heavy trading of ENVB shares despite a lack of news from the company this morning.
Via
InvestorPlace
Enveric Biosciences Reports Third Quarter 2024 Financial and Corporate Results
November 14, 2024
From
Enveric Biosciences
Via
Business Wire
Enveric Biosciences Out-Licenses Key Program To MycoMedica In $62M Deal
November 12, 2024
Enveric licenses EB-002 to MycoMedica for neuropsychiatric treatment, focusing on EB-003's development with potential milestones up to $62M.
Via
Benzinga
Enveric Biosciences Signs Out-Licensing Agreement with MycoMedica Life Sciences for EB-002
November 12, 2024
From
Enveric Biosciences, Inc.
Via
Business Wire
Enveric Biosciences Announces Broad Range of Patent Issuances
November 04, 2024
From
Enveric Biosciences
Via
Business Wire
Enveric Biosciences Expands Mental Health Patent Portfolio With 5 New Additions
November 04, 2024
Enveric Biosciences expands its patent portfolio with five new U.S. patents, supporting treatments for depression, anxiety and epilepsy.
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
12 Health Care Stocks Moving In Wednesday's After-Market Session
October 23, 2024
Via
Benzinga
Enveric Biosciences Advances Testing Of Its Non-Hallucinogenic Psychedelic
October 15, 2024
Enveric Biosciences announces positive preclinical results for EB-003, showcasing its potential as a safe and effective treatment for mental health disorders.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
October 15, 2024
Via
Benzinga
Enveric Biosciences Announces Positive Pharmacology and Safety Data for Lead Product, EB-003
October 15, 2024
From
Enveric Biosciences
Via
Business Wire
Psychedelics 2.0: Companies Explore Safer, More Targeted Therapies
October 04, 2024
Companies are developing safer, targeted psychedelic therapies aimed at reducing risks and improving mental health treatment options.
Via
Benzinga
Enveric Biosciences Presents Data Highlighting Development of EB-003 at European Behavioral Pharmacology Society Biennial Workshop
September 26, 2024
From
Enveric Biosciences
Via
Business Wire
Non-Hallucinogenic Psychedelic Treatment For Anxiety And Depression In Pre-Clinical Models: Enveric Biosciences' Breakthrough Research
September 25, 2024
Psychedelics biotech company Enveric Biosciences (NASDAQ: ENVB) has presented research highlighting the company's lead compound, EB-003 at the 7th Neuropsychiatric Drug Summit. The conference is being...
Via
Benzinga
Enveric Biosciences Presents Data on Lead Product Candidate, EB-003, at 7th Neuropsychiatric Drug Summit
September 25, 2024
From
Enveric Biosciences
Via
Business Wire
Enveric Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 04, 2024
From
Enveric Biosciences
Via
Business Wire
Aries Science & Technology and Enveric Biosciences Announce Issuance of Key US Patent Under Aries’ License for Treatment of Radiation Dermatitis and Other Conditions
August 13, 2024
From
Enveric Biosciences
Via
Business Wire
ENVB Stock Earnings: Enveric Biosciences Beats EPS for Q2 2024
August 12, 2024
ENVB stock results show that Enveric Biosciences beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Enveric Biosciences Reports Second Quarter 2024 Financial and Corporate Results
August 12, 2024
From
Enveric Biosciences
Via
Business Wire
Why Is Imunon (IMNN) Stock Up 259% Today?
July 30, 2024
Imunon stock is up on Tuesday with heavy trading of IMNN shares after posting positive results from a Phase 2 clinical trial.
Via
InvestorPlace
Why Is Ekso Bionics (EKSO) Stock Down 15% Today?
July 30, 2024
Ekso Bionics stock is down on Tuesday as investors in the company react to its lackluster earnings report for the second quarter of the year.
Via
InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
July 30, 2024
Pre-market stock movers are a hot topic as we jump into all of the biggest news that has shares heading higher and lower on Tuesday morning!
Via
InvestorPlace
Why Merck Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
July 30, 2024
Via
Benzinga
Why F5 Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket
July 30, 2024
Via
Benzinga
Non-Hallucinogenic Psychedelic Treatment For Mental Health Disorders Shows Potential To Be Dosed Orally
July 25, 2024
Via
Benzinga
Enveric Biosciences Announces Preclinical Results Confirming Potential of EB-003 to be Dosed Orally
July 25, 2024
From
Enveric Biosciences
Via
Business Wire
Aries Science & Technology and Enveric Biosciences Announce Licensing Agreement
July 15, 2024
From
Enveric Biosciences
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.